<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39347386</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?</ArticleTitle><Pagination><StartPage>e38085</StartPage><MedlinePgn>e38085</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38085</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38085</ELocationID><Abstract><AbstractText>The COVID-19 disease continues to cause complications and deaths worldwide. Identifying effective immune protection strategies remains crucial to address this ongoing challenge. The Bacillus Calmette-Guérin (BCG) vaccine, developed initially to prevent pulmonary tuberculosis, has gained relevance due to its ability to induce cross-protection against other pathogens of the airways. This review summarizes research on the immunological protection provided by BCG, along with its primary clinical and therapeutic uses. It also explores the immunological features of COVID-19, the mechanisms implicated in host cell death, and its association with chronic pulmonary illnesses such as tuberculosis, which has led to complications in diagnosis and management. While vaccines against COVID-19 have been administered globally, uncertainty still exists about its effectiveness. Additionally, it is uncertain whether the utilization of BCG can regulate the immune response to pathogens such as SARS-CoV-2.</AbstractText><CopyrightInformation>© 2024 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peña-Bates</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lascurain</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de Enlace Científico, Faculty of Medicine, Universidad Nacional Autónoma de México en el Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Navarrete</LastName><ForeName>Vianney</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavez-Galan</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCG</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39347386</ArticleId><ArticleId IdType="pmc">PMC11437859</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38085</ArticleId><ArticleId IdType="pii">S2405-8440(24)14116-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization; Geneva . 2020. Coronavirus Disease (COVID-19): Weekly Epidemiological, Update 1.</Citation></Reference><Reference><Citation>World Health Organization, Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/.</Citation></Reference><Reference><Citation>Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003 Apr 19;361(9366):1319–1325. doi: 10.1016/s0140-6736(03)13077-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(03)13077-2</ArticleId><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. World Health Organization  Middle East respiratory syndrome coronavirus (MERS-CoV) 2018. http://www.who.int/emergencies/mers-cov/en/</Citation></Reference><Reference><Citation>Jackson B., Boni M.F., Bull M.J., Colleran A., Colquhoun R.M., et al. Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell. 2021 Sep 30;184(20):5179–5188.e8. doi: 10.1016/j.cell.2021.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.014</ArticleId><ArticleId IdType="pmc">PMC8367733</ArticleId><ArticleId IdType="pubmed">34499854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization; COVID-19 vaccine tracker and landscape Available from:: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Borobia A.M., Carcas A.J., Pérez-Olmeda M., Castaño L., Bertran M.J., García-Pérez J., et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomized, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121–130. doi: 10.1016/S0140-6736(21)01420-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01420-3</ArticleId><ArticleId IdType="pmc">PMC8233007</ArticleId><ArticleId IdType="pubmed">34181880</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson B., Boni M.F., Bull M.J., Colleran A., Colquhoun R.M., Darby A.C., et al. Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell. 2021 Sep 30;184(20):5179–5188.e8. doi: 10.1016/j.cell.2021.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.014</ArticleId><ArticleId IdType="pmc">PMC8367733</ArticleId><ArticleId IdType="pubmed">34499854</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar L.E., Molina-Cruz A., Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) Proc. Natl. Acad. Sci. U.S.A. 2020 Jul 28;117(30):17720–17726. doi: 10.1073/pnas.2008410117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2008410117</ArticleId><ArticleId IdType="pmc">PMC7395502</ArticleId><ArticleId IdType="pubmed">32647056</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J., Gu X., Li Y., Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. 2020 Sep;129 doi: 10.1016/j.biopha.2020.110393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110393</ArticleId><ArticleId IdType="pubmed">32559616</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J., Kox M., Stokman R., Gerretsen J., Diavatopoulos D.A., et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J. Infect. Dis. 2015 Dec 15;212(12):1930–1938. doi: 10.1093/infdis/jiv332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv332</ArticleId><ArticleId IdType="pubmed">26071565</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel C.J., Mayer C., Poch O., Thompson J.D. Characterization of accessory genes in coronavirus genomes. Virol. J. 2020 Aug 27;17(1):131. doi: 10.1186/s12985-020-01402-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01402-1</ArticleId><ArticleId IdType="pmc">PMC7450977</ArticleId><ArticleId IdType="pubmed">32854725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B., Shen X., He Y., Pan X., Liu F.L., Wang Y., et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 2021 Aug;31(8):847–860. doi: 10.1038/s41422-021-00519-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00519-4</ArticleId><ArticleId IdType="pmc">PMC8190750</ArticleId><ArticleId IdType="pubmed">34112954</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan C.A., Kuo L., Masters P.S., Vennema H., Rottier P.J. Coronavirus particle assembly: primary structure requirements of the membrane protein. J. Virol. 1998 Aug;72(8):6838–6850. doi: 10.1128/JVI.72.8.6838-6850.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.72.8.6838-6850.1998</ArticleId><ArticleId IdType="pmc">PMC109893</ArticleId><ArticleId IdType="pubmed">9658133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Yang M., He S., Wang Y., Chen X., Chen Y.Q., et al. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. Nat. Commun. 2021 May 11;12(1):2697. doi: 10.1038/s41467-021-23036-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23036-9</ArticleId><ArticleId IdType="pmc">PMC8113585</ArticleId><ArticleId IdType="pubmed">33976229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hoffmann M., Kleine-Weber H., Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020 May 21;78(4):779–784.e5. doi: 10.1016/j.molcel.2020.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupala C.S., Ye Y., Chen H., Su X.D., Liu H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem. Biophys. Res. Commun. 2022 Jan 29;590:34–41. doi: 10.1016/j.bbrc.2021.12.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.12.079</ArticleId><ArticleId IdType="pmc">PMC8702632</ArticleId><ArticleId IdType="pubmed">34968782</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 Apr 30;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., et al. Coronavirus is a possible cause of severe acute respiratory syndrome. Lancet. 2003 Apr 19;361(9366):1319–1325. doi: 10.1016/s0140-6736(03)13077-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(03)13077-2</ArticleId><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020 May;214 doi: 10.1016/j.clim.2020.108393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108393</ArticleId><ArticleId IdType="pmc">PMC7102614</ArticleId><ArticleId IdType="pubmed">32222466</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J.-W., Kim S.E., Kim Y., Kim E.J., Kim T., Kim T., et al. Updated clinical practice guidelines for the diagnosis and management of long COVID. Infect Chemother. 2024 Mar 13 doi: 10.3947/ic.2024.0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2024.0024</ArticleId><ArticleId IdType="pmc">PMC10990882</ArticleId><ArticleId IdType="pubmed">38527781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Karki R., Williams E.P., Yang D., Fitzpatrick E., Vogel P., et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 2021 Jul;22(7):829–838. doi: 10.1038/s41590-021-00937-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K., Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. 2021 Feb 2;7(2) doi: 10.1016/j.heliyon.2021.e06187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06187</ArticleId><ArticleId IdType="pmc">PMC7887388</ArticleId><ArticleId IdType="pubmed">33644468</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Gonzalez J., Chavez-Galan L., Falfán-Valencia R., Roldán I.B., Fricke-Galindo I., Veronica-Aguilar A., et al. Variant rs4986790 of toll-like receptor 4 affects the signaling and induces cell dysfunction in patients with severe COVID-19. Int. J. Infect. Dis. 2024 Jan;138:102–109. doi: 10.1016/j.ijid.2023.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.11.032</ArticleId><ArticleId IdType="pubmed">38029833</ArticleId></ArticleIdList></Reference><Reference><Citation>Planès R., Bert J.B., Tairi S., BenMohamed L., Bahraoui E. SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: a novel molecular target for COVID-19 interventions. Viruses. 2022 May 8;14(5):999. doi: 10.3390/v14050999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050999</ArticleId><ArticleId IdType="pmc">PMC9146335</ArticleId><ArticleId IdType="pubmed">35632741</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J.W., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife. 2021 Dec 6;10 doi: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C.G., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020 May 28;181(5):1016–1035.e19. doi: 10.1016/j.cell.2020.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi V., Nguyen H.O., Sozio F., Schioppa T., Gaudenzi C., Laffranchi M., et al. SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. JCI Insight. 2021 Sep 22;6(18) doi: 10.1172/jci.insight.150542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.150542</ArticleId><ArticleId IdType="pmc">PMC8492321</ArticleId><ArticleId IdType="pubmed">34375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Sluis R.M., Cham L.B., Gris‐Oliver A., Gammelgaard K.R., Pedersen J.G., Idorn M., et al. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J. 2022 May 16;41(10) doi: 10.15252/embj.2021109622.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021109622</ArticleId><ArticleId IdType="pmc">PMC9108609</ArticleId><ArticleId IdType="pubmed">35178710</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Thomas J., Soung A.L., Davis-Gardner M.E., Floyd K., Jin F., et al. CCR2 signaling restricts SARS-CoV-2 infection. mBio. 2022 Jun 28;13(3) doi: 10.1128/mbio.00259-22. Erratum for Vanderheiden et al.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00259-22</ArticleId><ArticleId IdType="pmc">PMC9239131</ArticleId><ArticleId IdType="pubmed">35420471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage S.L., Amaral E.P., Hilligan K.L., Laidlaw E., Rupert A., Namasivayan S., et al. Persistent oxidative stress and inflammasome activation in CD14highCD16- monocytes from COVID-19 patients. Front. Immunol. 2022 Jan 14;12 doi: 10.3389/fimmu.2021.799558.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.799558</ArticleId><ArticleId IdType="pmc">PMC8795739</ArticleId><ArticleId IdType="pubmed">35095880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcinkaya M., Liu W., Islam M.N., Kotini A.G., Gusarova G.A., Fidler T.P., et al. Modulation of the NLRP3 inflammasome by sars-CoV-2 envelope protein. Sci. Rep. 2021 Dec 24;11(1) doi: 10.1038/s41598-021-04133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04133-7</ArticleId><ArticleId IdType="pmc">PMC8709866</ArticleId><ArticleId IdType="pubmed">34952919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat. Commun. 2021 Aug 2;12(1):4664. doi: 10.1038/s41467-021-25015-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25015-6</ArticleId><ArticleId IdType="pmc">PMC8329225</ArticleId><ArticleId IdType="pubmed">34341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios Y., Ruiz A., Ramón-Luing L.A., Ocaña-Guzman R., Barreto-Rodriguez O., Sánchez-Monciváis A., et al. Severe COVID-19 patients show an increase in soluble TNFR1 and ADAM17, with a relationship to mortality. Int. J. Mol. Sci. 2021 Aug 5;22(16):8423. doi: 10.3390/ijms22168423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168423</ArticleId><ArticleId IdType="pmc">PMC8395100</ArticleId><ArticleId IdType="pubmed">34445140</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios Y., Ramón-Luing L.A., Ruiz A., García-Martínez A., Sánchez-Monciváis A., Barreto-Rodríguez O., et al. COVID-19 patients with high TNF/IFN-γ levels show hallmarks of PANoptosis, an inflammatory cell death. Microbes Infect. 2023 Jun 30 doi: 10.1016/j.micinf.2023.105179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2023.105179</ArticleId><ArticleId IdType="pubmed">37394112</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I., Buendía-Roldán I., Ruiz A., Palacios Y., Pérez-Rubio G., de Jesus Hernández-Zenteno R., Reyes-Melendres F., et al. TNFRSF1B and TNF variants are associated with differences in levels of soluble tumor necrosis factor receptors in patients with severe COVID-19. J. Infect. Dis. 2022 Sep 13;226(5):778–787. doi: 10.1093/infdis/jiac101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac101</ArticleId><ArticleId IdType="pmc">PMC8992340</ArticleId><ArticleId IdType="pubmed">35294530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I., Martínez-Morales A., Chávez-Galán L., Ocaña-Guzmán R., Buendía-Roldán I., et al. IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19. Front. Immunol. 2022 Jul 29;13 doi: 10.3389/fimmu.2022.949413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.949413</ArticleId><ArticleId IdType="pmc">PMC9374460</ArticleId><ArticleId IdType="pubmed">35967349</ArticleId></ArticleIdList></Reference><Reference><Citation>André S., Picard M., Cezar R., Roux-Dalvai F., Alleaume-Butaux A., Soundaramourty C., et al. T cell apoptosis characterizes severe Covid-19 disease. Cell Death Differ. 2022 Aug;29(8):1486–1499. doi: 10.1038/s41418-022-00936-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-00936-x</ArticleId><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Zhang Y., Guan Z., Li H., Ye M., Chen X., Shen J., Zhou Y., Shi Z.L., Zhou P., Peng K. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct. Targeted Ther. 2020 Oct 9;5(1):235. doi: 10.1038/s41392-020-00334-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00334-0</ArticleId><ArticleId IdType="pmc">PMC7545816</ArticleId><ArticleId IdType="pubmed">33037188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Guo R., Lei L., Liu H., Wang Y., Wang Y., et al. COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J. Leukoc. Biol. 2021 Jan;109(1):13–22. doi: 10.1002/JLB.4HI0720-470R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4HI0720-470R</ArticleId><ArticleId IdType="pmc">PMC7675546</ArticleId><ArticleId IdType="pubmed">33040384</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersisyan S.A., Shkurnikov M.Y., Zhiyanov A.P., Novosad V.O., Tonevitsky A.G. Differences in presentation of SARS-CoV-2 omicron strain variant BA.1-BA.5 peptides by HLA molecules. Dokl. Biochem. Biophys. 2022 Dec;507(1):298–301. doi: 10.1134/S1607672922060084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S1607672922060084</ArticleId><ArticleId IdType="pmc">PMC9926403</ArticleId><ArticleId IdType="pubmed">36786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H.Y., Zhang M., Yang C.X., Zhang N., Wang X.C., Yang X.P., et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. 2020 May;17(5):541–543. doi: 10.1038/s41423-020-0401-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0401-3</ArticleId><ArticleId IdType="pmc">PMC7091621</ArticleId><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China. Clin. Infect. Dis. 2020 Jul 28;71(15):762–768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Idiz U.O., Yurttas T.T., Degirmencioglu S., Orhan B., Erdogan E., Sevik H., et al. Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients. J. Med. Virol. 2022 Oct;94(10):4744–4753. doi: 10.1002/jmv.27917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27917</ArticleId><ArticleId IdType="pmc">PMC9348494</ArticleId><ArticleId IdType="pubmed">35667877</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamm L.M., Fathi A., Raadsen M.P., Mykytyn A.Z., Koch T., Spohn M., et al. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Reports Med. 2022 Jul 19;3(7) doi: 10.1016/j.xcrm.2022.100685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100685</ArticleId><ArticleId IdType="pmc">PMC9295383</ArticleId><ArticleId IdType="pubmed">35858586</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S., Meschiari M., Gibellini L., Bellinazzi C., Borella R., Fidanza L., et al. Marked T cell activation, senescence, exhaustion, and skewing towards TH17 in patients with COVID-19 pneumonia. Nat. Commun. 2020 Jul 6;11(1):3434. doi: 10.1038/s41467-020-17292-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17292-4</ArticleId><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutmair S., Unger S., Núñez N.G., Ingelfinger F., Alberti C., De Feo D., et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity. 2022 Feb 8;55(2):366–375. doi: 10.1016/j.immuni.2022.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8822770</ArticleId><ArticleId IdType="pubmed">35139354</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization; COVID-19 vaccine tracker and landscape Available from:: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Maaske J., Sproule S., Falsey A.R., Sobieszczyk M.E., Luetkemeyer A.F., Paulsen G.C., et al. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. Front. Immunol. 2023 Jan 13;13 doi: 10.3389/fimmu.2022.1062067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1062067</ArticleId><ArticleId IdType="pmc">PMC9881590</ArticleId><ArticleId IdType="pubmed">36713413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa K., Nascimento M.C., Asano M., Hirata H., Itoh Y., Kelly E.J., et al. One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan. Vaccine. 2023 Jun 29;41(29):4199–4205. doi: 10.1016/j.vaccine.2023.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.015</ArticleId><ArticleId IdType="pmc">PMC10237326</ArticleId><ArticleId IdType="pubmed">37271703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M.N., Kelly E.J., Seegobin S., Dargan P.I., Payne R., Libri V., et al. AZD2816 Study Group. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. Lancet Microbe. 2023 Nov;4(11):e863–e874. doi: 10.1016/S2666-5247(23)00177-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00177-5</ArticleId><ArticleId IdType="pubmed">37783221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sablerolles R.S.G., Rietdijk W.J.R., Goorhuis A., Postma D.F., Visser L.G., Geers D., et al. Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming. N. Engl. J. Med. 2022 Mar 10;386(10):951–963. doi: 10.1056/NEJMoa2116747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116747</ArticleId><ArticleId IdType="pmc">PMC8796791</ArticleId><ArticleId IdType="pubmed">35045226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med. 2022 Mar 3;386(9):847–860. doi: 10.1056/NEJMoa2117608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117608</ArticleId><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatullin A.I., Shcheblyakov D.V., Dzharullaeva A.S., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887–897. doi: 10.1016/S0140-6736(20)31866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Martynova E., Hamza S., Garanina E.E., Kabwe E., Markelova M., Shakirova V., et al. Long term immune response produced by the SputnikV vaccine. Long term immune response produced by the SputnikV vaccine. Int. J. Mol. Sci. 2021 Oct 18;22(20) doi: 10.3390/ijms222011211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011211</ArticleId><ArticleId IdType="pmc">PMC8537212</ArticleId><ArticleId IdType="pubmed">34681885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I.T., Cosgrove C.A., Moore P., Bethune C., Nally R., Bula M., et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lancet Infect. Dis. 2023 Sep 1;23(9):1007–1019. doi: 10.1016/S1473-3099(23)00295-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00295-5</ArticleId><ArticleId IdType="pubmed">37348519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Ackerson B.K., et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect. Dis. 2022 Dec;22(12):1663–1665. doi: 10.1016/S1473-3099(22)00692-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00692-2</ArticleId><ArticleId IdType="pmc">PMC9597567</ArticleId><ArticleId IdType="pubmed">36306800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor O., Zuckerman N.S., Hazan I., Fluss R., Ash N., Ginish N., et al. BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. J. Clin. Epidemiol. 2022 Feb;142:38–44. doi: 10.1016/j.jclinepi.2021.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.10.011</ArticleId><ArticleId IdType="pmc">PMC8553421</ArticleId><ArticleId IdType="pubmed">34715314</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N. Engl. J. Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Available from: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19.</Citation></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021 Feb 4;384(5):403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios R., Batista A.P., Albuquerque C.S.N., Patiño E.G., Santos J. do P., Tilli Reis Pessoa Conde M., et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN Journal. 2021 doi: 10.2139/ssrn.3822780.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3822780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., Wu Q., Pan H., Li M., Yang J., Wang L., et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 2022 Apr;22(4):483–495. doi: 10.1016/S1473-3099(21)00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Zhang Y., Huang B., Deng W., Quan Y., Wang W., et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020 Aug 6;182(3):713–721.e9. doi: 10.1016/j.cell.2020.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7275151</ArticleId><ArticleId IdType="pubmed">32778225</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewandara C., Aberathna I.S., Pushpakumara P.D., Kamaladasa A., Guruge D., Wijesinghe A., et al. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun Inflamm Dis. 2022 Jun;10(6) doi: 10.1002/iid3.621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.621</ArticleId><ArticleId IdType="pmc">PMC9091995</ArticleId><ArticleId IdType="pubmed">35634958</ArticleId></ArticleIdList></Reference><Reference><Citation>Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP.</Citation></Reference><Reference><Citation>Crotty S. Hybrid immunity. Science. 2021;372(6549):1392–1393.</Citation></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L.S., Ash N., et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N. Engl. J. Med. 2022 Jun 9;386(23):2201–2212. doi: 10.1056/NEJMoa2118946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina A.A., Pogorelyy M.V., Kirk A.M., Crawford J.C., Allen E.K., Chou C.H., et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat. Immunol. 2022 May;23(5):781–790. doi: 10.1038/s41590-022-01184-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01184-4</ArticleId><ArticleId IdType="pmc">PMC9106845</ArticleId><ArticleId IdType="pubmed">35383307</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadian M., Hassanzadeh S.M., Safarchi A., Douraghi M. Genomic characteristics of two most widely used BCG vaccine strains: Danish 1331 and Pasteur 1173P2. BMC Genom. 2022 Aug 21;23(1):609. doi: 10.1186/s12864-022-08826-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-022-08826-9</ArticleId><ArticleId IdType="pmc">PMC9392950</ArticleId><ArticleId IdType="pubmed">35987561</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfyffer G.E. Book section. Mycobacterium: general characteristics, laboratory detection, and staining procedures. Manual of Clinical Microbiology. 2015:536–537p. ISBN 978-1-55581-738-1.</Citation></Reference><Reference><Citation>Lagune M., Petit C., Sotomayor F.V., Johansen M.D., Beckham K.S.H., Ritter C., et al. Conserved and specialized functions of Type VII secretion systems in non-tuberculous mycobacteria. Microbiology (Reading, England) 2021 Jul;167(7) doi: 10.1099/mic.0.001054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mic.0.001054</ArticleId><ArticleId IdType="pubmed">34224347</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley S.A., Raghavan S., Hwang W.W., Cox J.S. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc. Natl. Acad. Sci. U.S.A. 2003 Oct 28;100(22):13001–13006. doi: 10.1073/pnas.2235593100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2235593100</ArticleId><ArticleId IdType="pmc">PMC240734</ArticleId><ArticleId IdType="pubmed">14557536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. U.S.A. 2007 Mar 27;104(13):5596–5601. doi: 10.1073/pnas.0700869104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700869104</ArticleId><ArticleId IdType="pmc">PMC1838518</ArticleId><ArticleId IdType="pubmed">17372194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross M.L., Aldwell F.E., Griffin J.F., Mackintosh C.G. Intracellular survival of virulent Mycobacterium bovis and M. bovis BCG in ferret macrophages. Vet. Microbiol. 1999 Apr 19;66(3):235–243. doi: 10.1016/s0378-1135(99)00011-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0378-1135(99)00011-5</ArticleId><ArticleId IdType="pubmed">10227125</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldwein K.A., Liang M.D., Andresen T.K., Thomas K.E., Marty A.M., Cuesta N., et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukoc. Biol. 2003 Aug;74(2):277–286. doi: 10.1189/jlb.0103026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0103026</ArticleId><ArticleId IdType="pubmed">12885945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi M.C., Teloni R., Giannoni F., Pardini M., Sargentini V., Brunori L., et al. Mycobacterium bovis bacillus Calmette-Guerin infects DC-SIGN- dendritic cells and causes the inhibition of IL-12 and the enhancement of IL-10 pro-duction. J. Leukoc. Biol. 2005;78(1):106–113. doi: 10.1189/jlb.0105037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0105037</ArticleId><ArticleId IdType="pubmed">15845642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann E., Sanz J., Dunn J.L., Khan N., Mendonça L.E., Pacis A., et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell. 2018 Jan 11;172(1–2):176–190.e19. doi: 10.1016/j.cell.2017.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.031</ArticleId><ArticleId IdType="pubmed">29328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Pando R., Shin S.J., Clark S., Casonato S., Becerril-Zambrano M., Kim H., et al. Construction and characterization of the Mycobacterium tuberculosis sigE fadD26 unmarked double mutant as a vaccine candidate. Infect. Immun. 2019 Dec 17;88(1) doi: 10.1128/IAI.00496-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00496-19</ArticleId><ArticleId IdType="pmc">PMC6921654</ArticleId><ArticleId IdType="pubmed">31591165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemes E., Geldenhuys H., Rozot V., Rutkowski K.T., Ratangee F., Bilek N., et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 2018 Jul 12;379(2):138–149. doi: 10.1056/NEJMoa1714021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1714021</ArticleId><ArticleId IdType="pmc">PMC5937161</ArticleId><ArticleId IdType="pubmed">29996082</ArticleId></ArticleIdList></Reference><Reference><Citation>Debisarun P.A., Kilic G., de Bree L.C.J., Pennings L.J., van Ingen J., Benn C.S., et al. The impact of BCG dose and revaccination on trained immunity. Clin Immunol. 2023 Jan;246 doi: 10.1016/j.clim.2022.109208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109208</ArticleId><ArticleId IdType="pubmed">36565972</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustman D.L., Wang L., Okubo Y., Burger D., Ban L., Man G., et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One. 2012;7(8) doi: 10.1371/journal.pone.0041756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041756</ArticleId><ArticleId IdType="pmc">PMC3414482</ArticleId><ArticleId IdType="pubmed">22905105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristori G., Romano S., Cannoni S., Visconti A., Tinelli E., Mendozzi L., et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014 Jan 7;82(1):41–48. doi: 10.1212/01.wnl.0000438216.93319.ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000438216.93319.ab</ArticleId><ArticleId IdType="pmc">PMC3873620</ArticleId><ArticleId IdType="pubmed">24306002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippens C., Garnier L., Guyonvarc’h P.M., Santiago-Raber M.L., Hugues S. Extended freeze-dried BCG instructed pDCs induce suppressive Tregs and dampen EAE. Front. Immunol. 2018 Nov 29;9:2777. doi: 10.3389/fimmu.2018.02777.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02777</ArticleId><ArticleId IdType="pmc">PMC6281986</ArticleId><ArticleId IdType="pubmed">30555468</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyl-de Groot C.A., Vermorken J.B., Hanna M.G., Verboom P., Groot M.T., Bonsel G.J., et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005 Mar 18;23(17–18):2379–2387. doi: 10.1016/j.vaccine.2005.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.01.015</ArticleId><ArticleId IdType="pubmed">15755632</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinsky C.M., Hirshaut Y., Oettgen H.F. Treatment of malignant melanoma by intratumoral injection of BCG. Natl. Cancer Inst. Monogr. 1973 Dec;39:225–228. PMID: 4595322.</Citation><ArticleIdList><ArticleId IdType="pubmed">4595322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremenovic M., Chan A.A., Feng B., Bäriswyl L., Robatel S., Gruber T., et al. BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma. J Immunother Cancer. 2022 Jun;10(6) doi: 10.1136/jitc-2021-004133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-004133</ArticleId><ArticleId IdType="pmc">PMC9226922</ArticleId><ArticleId IdType="pubmed">35732347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamat A.M., Shore N., Hahn N., Alanee S., Nishiyama H., Shariat S., et al. KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 2020 Apr;16(10):507–516. doi: 10.2217/fon-2019-0817.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2019-0817</ArticleId><ArticleId IdType="pubmed">32162533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran K.A., Pernet E., Sadeghi M., Downey J., Chronopoulos J., Lapshina E., et al. BCG immunization induces CX3CR1hi effector memory T cells to provide cross-protection via IFN-γ-mediated trained immunity. Nat. Immunol. 2024 Mar;25(3):418–431. doi: 10.1038/s41590-023-01739-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01739-z</ArticleId><ArticleId IdType="pubmed">38225437</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.Y., Oosting M., et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018 Jan 10;23(1):89–100.e5. doi: 10.1016/j.chom.2017.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.12.010</ArticleId><ArticleId IdType="pubmed">29324233</ArticleId></ArticleIdList></Reference><Reference><Citation>Abarca K., Rey-Jurado E., Muñoz-Durango N., Vázquez Y., Soto J.A., Gálvez N.M.S., et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine. 2020 Oct 6;27 doi: 10.1016/j.eclinm.2020.100517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100517</ArticleId><ArticleId IdType="pmc">PMC7548429</ArticleId><ArticleId IdType="pubmed">33073219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S., Subramaniam R., Chen H., Smith A., Keshava S., Shams H. Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PLoS One. 2017 Jul 7;12(7) doi: 10.1371/journal.pone.0180143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180143</ArticleId><ArticleId IdType="pmc">PMC5501455</ArticleId><ArticleId IdType="pubmed">28686604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B.Z., Shuai H., Gong H.R., Hu J.C., Yan B., Yuen T.T., et al. Bacillus Calmette-Guérin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight. 2022 Jun 8;7(11) doi: 10.1172/jci.insight.157393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157393</ArticleId><ArticleId IdType="pmc">PMC9220951</ArticleId><ArticleId IdType="pubmed">35446790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann E., Khan N., Tran K.A., Ulndreaj A., Pernet E., Fontes G., et al. BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep. 2022 Mar 8;38(10) doi: 10.1016/j.celrep.2022.110502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110502</ArticleId><ArticleId IdType="pmc">PMC8858710</ArticleId><ArticleId IdType="pubmed">35235831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambe R.C., Bhalla S., Alvarado A., Barragan J., Cervantes J. Bacille-Calmette-Guerin modulates human macrophage and dendritic cell response to SARS-CoV-2 S-glycoprotein. Infect. Med. 2023 Sep 4;2(3):241–245. doi: 10.1016/j.imj.2023.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imj.2023.08.004</ArticleId><ArticleId IdType="pmc">PMC10699688</ArticleId><ArticleId IdType="pubmed">38073885</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 2016 Sep;16(9):553–565. doi: 10.1038/nri.2016.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.70</ArticleId><ArticleId IdType="pmc">PMC5001910</ArticleId><ArticleId IdType="pubmed">27396447</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita Y., Sato R., Ikeda T., Sakagami T. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis. Vaccine. 2020 Sep 22;38(41):6352–6356. doi: 10.1016/j.vaccine.2020.08.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.08.045</ArticleId><ArticleId IdType="pmc">PMC7440160</ArticleId><ArticleId IdType="pubmed">32863070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo Y., To K.K.W., Zhou R., Liu L., Cao T., Huang H., et al. Mitochondrial dysfunction associates with acute T lymphocytopenia and impaired functionality in COVID-19 patients. Front. Immunol. 2022 Jan 14;12 doi: 10.3389/fimmu.2021.799896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.799896</ArticleId><ArticleId IdType="pmc">PMC8795605</ArticleId><ArticleId IdType="pubmed">35095881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhao J., Wang H., Wang W., Su X., Liao X., et al. Metabolic defects of peripheral T cells in COVID-19 patients. J. Immunol. 2021 Jun 15;206(12):2900–2908. doi: 10.4049/jimmunol.2100068.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100068</ArticleId><ArticleId IdType="pubmed">34049969</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Shen H.H. Neonatal bacillus Calmette-Guérin vaccination inhibits de novo allergic inflammatory response in mice via alteration of CD4+CD25+ T-regulatory cells. Acta Pharmacol. Sin. 2009 Jan;30(1):125–133. doi: 10.1038/aps.2008.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2008.3</ArticleId><ArticleId IdType="pmc">PMC4006540</ArticleId><ArticleId IdType="pubmed">19060917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L.L., Wei X.S., Zhang M., Niu Y.R., Zhou Q. The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells. Front. Immunol. 2018 Mar 22;9:583. doi: 10.3389/fimmu.2018.00583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00583</ArticleId><ArticleId IdType="pmc">PMC5874323</ArticleId><ArticleId IdType="pubmed">29623079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Bäumel M., Männel D.N., Howard O.M.Z., Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 2007 Jul 1;179(1):154–161. doi: 10.4049/jimmunol.179.1.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.1.154</ArticleId><ArticleId IdType="pubmed">17579033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A., Kumar N.P., Padmapriyadarsini C., Nancy A., Selvaraj N., Karunanithi K., et al. Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. J. Infect. 2021 Sep 1;83(3):339–346. doi: 10.1016/j.jinf.2021.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.07.029</ArticleId><ArticleId IdType="pmc">PMC8316716</ArticleId><ArticleId IdType="pubmed">34329676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebina-Shibuya R., Horita N., Namkoong H., Kaneko T. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19. Respirology. 2020 Aug;25(8):898–899. doi: 10.1111/resp.13885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.13885</ArticleId><ArticleId IdType="pmc">PMC7323121</ArticleId><ArticleId IdType="pubmed">32558034</ArticleId></ArticleIdList></Reference><Reference><Citation>Urashima M., Otani K., Hasegawa Y., Akutsu T. BCG vaccination and mortality of COVID-19 across 173 countries: an ecological study. Int. J. Environ. Res. Publ. Health. 2020 Aug 3;17(15):5589. doi: 10.3390/ijerph17155589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17155589</ArticleId><ArticleId IdType="pmc">PMC7432030</ArticleId><ArticleId IdType="pubmed">32756371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita M., Tanaka M. Impact of routine infant BCG vaccination on COVID-19. J. Infect. 2020 Oct;81(4):625–633. doi: 10.1016/j.jinf.2020.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.013</ArticleId><ArticleId IdType="pmc">PMC7419263</ArticleId><ArticleId IdType="pubmed">32795481</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinger D., Blass I., Rappoport N., Linial M. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: a multivariable analysis. Vaccines (Basel) 2020 Jul 11;8(3):378. doi: 10.3390/vaccines8030378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030378</ArticleId><ArticleId IdType="pmc">PMC7563451</ArticleId><ArticleId IdType="pubmed">32664505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gursel M., Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of the SARS-CoV-2 pandemic? Allergy. 2020 Jul;75(7):1815–1819. doi: 10.1111/all.14345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14345</ArticleId><ArticleId IdType="pmc">PMC7267226</ArticleId><ArticleId IdType="pubmed">32339299</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton C.M., van Wijk R.C., Mockeliunas L., Simonsson U.S.H., McHarry K., van den Hoogen G., et al. BCG CORONA Consortium Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: a double-blind, randomized, controlled, phase 3 trial. EClinicalMedicine. 2022 Jun;48 doi: 10.1016/j.eclinm.2022.101414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101414</ArticleId><ArticleId IdType="pmc">PMC9098089</ArticleId><ArticleId IdType="pubmed">35582122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Doesschate T., van der Vaart T.W., Debisarun P.A., Taks E., Moorlag S.J.C.F.M., Paternotte N., et al. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. Clin. Microbiol. Infect. 2022 Sep;28(9):1278–1285. doi: 10.1016/j.cmi.2022.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC9046133</ArticleId><ArticleId IdType="pubmed">35489606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet L.F., Messina N.L., Orsini F., Moore C.L., Abruzzo V., Barry S., et al. BRACE Trial Consortium Group Randomized trial of BCG vaccine to protect against covid-19 in health care workers. N. Engl. J. Med. 2023 Apr 27;388(17):1582–1596. doi: 10.1056/NEJMoa2212616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2212616</ArticleId><ArticleId IdType="pmc">PMC10497190</ArticleId><ArticleId IdType="pubmed">37099341</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus J., ten Doesschate T., Gumbs C., van Werkhoven C.H., van der Vaart T.W., Janssen A.B., et al. CG vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial. mBio. 2023 Apr 25;14(2) doi: 10.1128/mbio.00356-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00356-23</ArticleId><ArticleId IdType="pmc">PMC10128007</ArticleId><ArticleId IdType="pubmed">36976004</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos A.P., Werneck G.L., Dalvi A.P.R., dos Santos C.C., Tierno P.F.G.M.M., Condelo H.S., et al. The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil. Int. J. Infect. Dis. 2023 May;130:8–16. doi: 10.1016/j.ijid.2023.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.02.014</ArticleId><ArticleId IdType="pmc">PMC9972589</ArticleId><ArticleId IdType="pubmed">36841502</ArticleId></ArticleIdList></Reference><Reference><Citation>Koekenbier E.L., Fohse K., van de Maat J.S., Oosterheert J.J., van Nieuwkoop C., Hoogerwerf J.J., et al. Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin. Microbiol. Infect. 2023 Jun;29(6):781–788. doi: 10.1016/j.cmi.2023.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.01.019</ArticleId><ArticleId IdType="pmc">PMC9892323</ArticleId><ArticleId IdType="pubmed">36736662</ArticleId></ArticleIdList></Reference><Reference><Citation>Moorlag S.J.C.F.M., Taks E., Ten Doesschate T., Van Der Vaart T.W., Janssen A.B., Müller L., et al. Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic. Clin. Infect. Dis. 2022 Aug 24;75(1):e938–e946. doi: 10.1093/cid/ciac182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac182</ArticleId><ArticleId IdType="pmc">PMC8903481</ArticleId><ArticleId IdType="pubmed">35247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilika M., Taks E., Dolianitis K., Kotsaki A., Leventogiannis K., Damoulari C., et al. ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk. Front. Immunol. 2022 Jul 5;13 doi: 10.3389/fimmu.2022.873067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.873067</ArticleId><ArticleId IdType="pmc">PMC9294453</ArticleId><ArticleId IdType="pubmed">35865520</ArticleId></ArticleIdList></Reference><Reference><Citation>Specht A.G., Ginese M., Kurtz S.L., Elkins K.L., Specht H., Beamer G. Host genetic background influences BCG-induced antibodies cross-reactive to SARS-CoV-2 spike protein. Vaccines (Basel) 2024 Feb 26;12(3):242. doi: 10.3390/vaccines12030242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030242</ArticleId><ArticleId IdType="pmc">PMC10975245</ArticleId><ArticleId IdType="pubmed">38543876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilligan K.L., Namasivayam S., Clancy C.S., O'Mard D., Oland S.D., Robertson S.J., et al. Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. J. Exp. Med. 2022 Feb 7;219(2) doi: 10.1084/jem.20211862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211862</ArticleId><ArticleId IdType="pmc">PMC8669500</ArticleId><ArticleId IdType="pubmed">34889942</ArticleId></ArticleIdList></Reference><Reference><Citation>White A.D., Sibley L., Sarfas C., Morrison A.L., Bewley K., Churchward C., et al. Influence of aerosol delivered BCG vaccination on immunological and disease parameters following SARS-CoV-2 challenge in rhesus macaques. Front. Immunol. 2022 Feb 9;12 doi: 10.3389/fimmu.2021.801799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.801799</ArticleId><ArticleId IdType="pmc">PMC8863871</ArticleId><ArticleId IdType="pubmed">35222355</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah A.M., Hill-Cawthorne G.A., Otto T.D., Coll F., Guerra-Assunção J.A., Gao G., et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci. Rep. 2015 Oct 21;5 doi: 10.1038/srep15443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15443</ArticleId><ArticleId IdType="pmc">PMC4614345</ArticleId><ArticleId IdType="pubmed">26487098</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Ru H.W., Chen F.Z., Jin C.Y., Sun R.F., Fan X.Y., et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol. Ther. 2016 Feb;24(2):398–405. doi: 10.1038/mt.2015.216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2015.216</ArticleId><ArticleId IdType="pmc">PMC4817822</ArticleId><ArticleId IdType="pubmed">26643797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Martinez E., Falfán-Valencia R., Pérez-Rubio G., Andrade W.A., Rojas-Serrano J., Ambrocio-Ortiz E., et al. Effect of BCG revaccination on occupationally exposed medical personnel vaccinated against SARS-CoV-2. Cells. 2021 Nov 15;10(11):3179. doi: 10.3390/cells10113179.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113179</ArticleId><ArticleId IdType="pmc">PMC8617982</ArticleId><ArticleId IdType="pubmed">34831403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakshit S., Adiga V., Ahmed A., Parthiban C., Chetan Kumar N., Dwarkanath P., et al. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. Front. Immunol. 2022 Oct 4;13 doi: 10.3389/fimmu.2022.985938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.985938</ArticleId><ArticleId IdType="pmc">PMC9577398</ArticleId><ArticleId IdType="pubmed">36268023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalalizadeh M., Buosi K., Dionato F.A.V., Dal Col L.S.B., Giacomelli C.F., Ferrari K.L., et al. Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: clinical evolution, adverse events, and humoral immune response. J. Intern. Med. 2022 Oct;292(4):654–666. doi: 10.1111/joim.13523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13523</ArticleId><ArticleId IdType="pmc">PMC9347570</ArticleId><ArticleId IdType="pubmed">35599154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionato F.A.V., Jalalizadeh M., Buosi K., Visacri M.B., Dal Col L.S.B., Giacomelli C.F., et al. BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial. Vaccine. 2022 Jul 30;40(32):4603–4608. doi: 10.1016/j.vaccine.2022.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.039</ArticleId><ArticleId IdType="pmc">PMC9212358</ArticleId><ArticleId IdType="pubmed">35738969</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. [ID: NCT02403505]. Available from: https://classic.clinicaltrials.gov/ProvidedDocs/05/NCT02403505/ICF_003.pdf.</Citation></Reference><Reference><Citation>Perera D.J., Domenech P., Babuadze G.G., Naghibosadat M., Alvarez F., Koger-Pease C., et al. BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine. iScience. 2023 Aug 11;26(9) doi: 10.1016/j.isci.2023.107612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107612</ArticleId><ArticleId IdType="pmc">PMC10475483</ArticleId><ArticleId IdType="pubmed">37670783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>